Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Canada.
Schizophr Res. 2011 Nov;132(2-3):121-4. doi: 10.1016/j.schres.2011.08.007. Epub 2011 Sep 3.
Neurexin-1 (NRXN1) modulates recruitment of NMDA receptors. Furthermore, clozapine reduces hyperactivity of NMDA receptors. Thus, regulation of the NRXN1 gene may mediate the efficacy of clozapine at reducing cortical hyperactivity. We examined the putative functional SNP, rs1045881, for association with schizophrenia, and the potential role of this SNP in clozapine response. The rs1045881 variant was not significantly associated with schizophrenia (N=302 case-control pairs), but with clozapine response (N=163; p=0.030). Baseline and BPRS scores after six months revealed a trend for rs1045881 genotype by treatment interaction (p=0.079). In the post hoc analysis, a significant association between BPRS negative symptoms score and genotype was observed (p=0.033). These results suggest that the rs1045881 NRXN1 polymorphism may influence clozapine response.
神经连接蛋白-1(NRXN1)调节 NMDA 受体的募集。此外,氯氮平可降低 NMDA 受体的过度活跃。因此,NRXN1 基因的调节可能介导氯氮平降低皮质过度活跃的疗效。我们研究了假定的功能性 SNP rs1045881 与精神分裂症的关联,以及该 SNP 在氯氮平反应中的潜在作用。rs1045881 变体与精神分裂症(N=302 病例对照对)无显著关联,但与氯氮平反应(N=163;p=0.030)相关。六个月后的基线和 BPRS 评分显示出 rs1045881 基因型与治疗的交互作用趋势(p=0.079)。在事后分析中,观察到 BPRS 阴性症状评分与基因型之间存在显著关联(p=0.033)。这些结果表明,NRXN1 多态性 rs1045881 可能影响氯氮平的反应。